Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.49 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6208002 | 1.00 | SPHK1 (0.49) | SPHK1HSD11B2BRD4TDP1NR1H2 | |
| SCHEMBL6208006 | 1.00 | SPHK1 (0.49) | SPHK1HSD11B2BRD4TDP1NR1H2 | |
| SCHEMBL8055345 | 0.96 | SPHK1 (0.48) | SPHK1HSD11B2BRD4TDP1NR1H2 | |
| SCHEMBL8053046 | 0.96 | SPHK1 (0.48) | SPHK1HSD11B2BRD4TDP1NR1H2 | |
| SCHEMBL13040191 | 0.96 | SPHK1 (0.48) | SPHK1HSD11B2BRD4TDP1NR1H2 | |
| SCHEMBL16053956 | 0.95 | SPHK1 (0.50) | SPHK1HSD11B2BRD4TDP1NR1H2 | |
| SCHEMBL15318844 | 0.92 | SPHK1 (0.48) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL1068504 | 0.92 | SPHK1 (0.48) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL1068506 | 0.92 | SPHK1 (0.48) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL16071281 | 0.89 | SPHK1 (0.58) | SPHK1HSD11B2BRD4NR1H2HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043115-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-10450325-B2 | Processes of preparing a JAK1 inhibitor and new forms thereto | INCYTE CORPORATION (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180099978-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | INCYTE CORPORATION | 2018-04-12 | — | — | US | disclosed |
| US-9802957-B2 | Processes of preparing a JAK1 inhibitor and new forms thereto | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802957-B2 | Processes of preparing a JAK1 inhibitor and new forms thereto | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150344497-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | INCYTE CORPORATION (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344497-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | INCYTE CORPORATION (US) | 2015-12-03 | — | — | US | disclosed |
| WO-2015168246-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | INCYTE CORPORATION (US) | 2015-11-05 | — | — | WO | disclosed |
| US-8796272-B2 | Glycine transporter-inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-08-05 | — | — | US | disclosed |
| US-8796272-B2 | Glycine transporter-inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20100063013-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-03-11 | — | — | US | disclosed |
| US-20100063013-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-03-11 | — | — | US | disclosed |
| WO-2008116302-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2008-10-02 | — | — | WO | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-0520336-A2 | Aldehyde derivatives and their use as calpain inhibitors | FUJIREBIO Inc. (JP) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450325-B2 | Processes of preparing a JAK1 inhibitor and new forms thereto | JAK1, JAK2, JAK3 | SPHK1 2466/4885HSD11B2 3374/4885BRD4 1930/4885 |
| US-20100063013-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSS, CTSB, CTSZ | SPHK1 2421/4885HSD11B2 2906/4885BRD4 2292/4885 |
| US-20180099978-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | JAK1, JAK2, JAK3 | SPHK1 2466/4885HSD11B2 3374/4885BRD4 1930/4885 |
| US-20150344497-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | JAK1, JAK2, JAK3 | SPHK1 2466/4885HSD11B2 3374/4885BRD4 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.